| Short Description : | Recombinant-Active-Human BPI-C-hFc-His protein was developed from mammalian cells and has a target region of C-hFc-His. For use in research applications. |
| Applications: | ELISA/WB |
| Host: | Mammalian Cells |
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Conjugation: | Unconjugated |
| Dilution Range: | Reconstitute in sterile water for a stock solution. |
| Formulation: | Lyophilized from a solution in PBS pH 7.4, 5% Trehalose, 5% Mannitol. |
| Storage Instruction: | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for one week. Store at-20 to-80°C for twelve months from the date of receipt. |
| Endotoxin: | <0.1 EU/Mu g of the protein by the LAL method. |
| Immunoreactivity: | Measured by its ability to inhibit LPS induced IL-8 secretion by human acute monocytic leukemia cells (THP-1). The ED50 for this effect is 0.4-2.4 ng/mL. |
| Gene Symbol: | BPI |
| Gene ID: | 671 |
| Uniprot ID: | BPI_HUMAN |
| Immunogen: | Homo sapiens (Human) |
| Immunogen Region: | Val32-Lys487 |
| Function | The cytotoxic action of BPI is limited to many species of Gram-negative bacteria.this specificity may be explained by a strong affinity of the very basic N-terminal half for the negatively charged lipopolysaccharides that are unique to the Gram-negative bacterial outer envelope. Has antibacterial activity against the Gram-negative bacterium P.aeruginosa, this activity is inhibited by LPS from P.aeruginosa. |
| Protein Name | Bactericidal Permeability-Increasing ProteinBpiCap 57 |
| Database Links | Reactome: R-HSA-166016Reactome: R-HSA-6798695Reactome: R-HSA-6803157 |
| Cellular Localisation | SecretedCytoplasmic Granule MembraneMembrane-Associated In Polymorphonuclear Leukocytes (Pmn) Granules |
| Alternative Protein Names | Bactericidal Permeability-Increasing Protein proteinBpi proteinCap 57 proteinBPI protein |
Information sourced from Uniprot.org
